Insmed Incorporated filings document formal disclosures for its commercial biopharmaceutical portfolio and respiratory and inflammatory pipeline. Recent Form 8-K reports furnish financial results, investor presentations, Regulation FD materials, clinical-study updates for ARIKAYCE and brensocatib, regulatory approval announcements for BRINSUPRI, and portfolio additions such as INS1148.
The company’s proxy materials describe board elections, executive compensation, equity awards, shareholder voting matters and governance practices. Other current reports document compensatory arrangements, director-transition disclosures, exhibits and Inline XBRL cover-page data tied to Insmed’s Nasdaq-listed common stock.
Insmed Inc’s Chief Legal Officer, Michael Alexander Smith, reported option exercises and share sales in company stock. On February 24, 2026, he exercised a stock option for 20,248 shares, converting a derivative security into common stock at a reported price of $17.07 per share.
On the same date, he sold a total of 24,774 shares of common stock in open-market transactions at weighted average prices of $153.93, $155.06, and $156.53 per share, under a Rule 10b5-1 trading plan adopted on November 7, 2025. After these transactions, he directly owned 51,871 common shares of Insmed.
INSMED Inc director David R. Brennan reported a bona fide gift of 6,000 shares of Common Stock. The gift was made on February 23, 2026 at a reported price of $0.00 per share, indicating it was a non-cash, charitable or personal transfer rather than a sale.
After this disposition, Brennan directly holds 60,933 shares of INSMED Common Stock. In addition, an indirect holding of 60,000 shares is reported as being held by a spouse revocable trust, reflecting shares associated with, but not directly owned by, the director.
INSMED Inc officer Michael Smith reported a proposed sale of 24,774 common shares, with an aggregate market value of $3,859,153 and an approximate sale date of February 24, 2026. The notice lists November 7, 2025 as the date of plan adoption or giving of instruction if relying on Rule 10b5-1.
Insmed Inc Chair and CEO William Lewis reported option exercises and share sales. On February 19, 2026, he exercised stock options for 6,259 and 4,440 shares, converting them into an equal number of Common Stock shares at grant prices of $30.46 and $17.16 per share.
On the same date, he sold a total of 10,699 Common Stock shares in open-market transactions at weighted average prices between $149.17 and $153.38, under a pre‑arranged Rule 10b5‑1 trading plan adopted on September 4, 2025. After these trades, he held 301,185 shares directly, plus indirect holdings of 233,924 shares through the Katie Procter Dynasty Trust and 50,500 shares through the William Lewis Family Legacy Trust.
INSM filings report insider stock sales by William Lewis. The filing lists multiple sales dated between 12/04/2025 and 02/19/2026, with reported sale amounts including 13,396, 3,009, 10,699, 19,215, 3,223, 2,357, 4,096, and other similar share quantities. The entries show transaction dates and numeric amounts associated with each sale.
Insmed Incorporated uses this Annual Report to outline its strategy as a global biopharma company focused on respiratory, immunology & inflammation, and neuro & other rare diseases. The company now has two commercial respiratory drugs: ARIKAYCE, an inhaled therapy for MAC lung disease with approvals in the US, Europe and Japan, and BRINSUPRI, an oral treatment for non-cystic fibrosis bronchiectasis approved in the US in August 2025 and by the European Commission in November 2025.
Insmed highlights large addressable markets in bronchiectasis and MAC lung disease and reports positive Phase 3 data for brensocatib (ASPEN) and positive Phase 2 results for TPIP in pulmonary arterial hypertension and PH-ILD, with multiple Phase 3 programs planned in 2026. Early-stage gene therapy programs INS1201 for Duchenne muscular dystrophy and INS1202 for ALS are in Phase 1 trials, while the ARIKAYCE post-marketing ENCORE study is fully enrolled with topline data expected by April 2026 to support potential full US approval and label expansion.
Insmed Incorporated reported strong growth for the fourth quarter and full year 2025 while remaining deeply loss-making and setting ambitious 2026 revenue goals. Total revenue reached $606.4 million in 2025, up from $363.7 million, driven by the U.S. launch of BRINSUPRI and continued ARIKAYCE expansion.
BRINSUPRI generated $144.6 million in Q4 and $172.7 million for 2025, while ARIKAYCE delivered $119.2 million in Q4 and $433.8 million for the year, representing 19% annual growth. Despite this, Insmed posted a 2025 net loss of $1.28 billion, as operating expenses rose to $1.85 billion. The company ended 2025 with approximately $1.4 billion in cash, cash equivalents, and marketable securities and guides for at least $1 billion in 2026 BRINSUPRI revenue and $450–$470 million from ARIKAYCE. Insmed also highlighted Orphan Drug Designation for TPIP in pulmonary arterial hypertension and ongoing late-stage studies. Separately, director David W.J. McGirr will not stand for re-election at the 2026 annual meeting but will continue serving until then.
INSMED Inc. director David W. J. McGirr reported a bona fide gift transfer of 53,400 shares of common stock on February 9, 2026. The filing shows 53,400 shares moved from his direct holdings to indirect ownership through a family trust, leaving 44,323 shares held directly and 53,400 shares held indirectly.
INSMED Inc.’s Chair and CEO William Lewis reported option exercises and share sales on common stock. On February 9, 2026, he exercised stock options for 4,440 shares at $17.16 and 6,259 shares at $30.46 per share, converting them into common stock. The same day, he sold 4,888 shares at a weighted average price of $147.17, 7,221 shares at $148.02, and 1,287 shares at $148.83, under a Rule 10b5-1 trading plan adopted on September 4, 2025. After these transactions, he directly owned 301,185 common shares and had indirect ownership of 233,924 shares through the Katie Procter Dynasty Trust and 50,500 shares through the William Lewis Family Legacy Trust.
William Lewis filed a Rule 144 notice to sell 13396 Insmed common shares. The filing lists Merrill Lynch as broker, with the shares to be sold on NASDAQ and an aggregate market value of 1979774. It notes 213273469 common shares outstanding.
The shares to be sold were acquired through stock plan activity, including 10699 shares on 02/09/2026 and 2697 shares on 02/01/2026. The notice also details several prior open-market sales over the past three months with disclosed share counts and gross proceeds.